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Abstract
OBJECTIVE: To investigate the combinatorial ef-
fects of Naomai Yihao (NMYH) Capsules (脑脉一号
胶 囊) and vascular endothelial growth factor
(VEGF) gene-transfected bone marrow mesenchy-
mal stem cells (BMSCs) on angiogenesis in cerebral
ischemic tissues in rats and the mechanism.
METHOD: BMSCs were isolated and cultured from
bone marrow by an adherence method. Then, BM-
SCs were transfected with the eukaryotic expres-
sion plasmid pEGFP-VEGF165 by positive ionic lipo-
some transfection. A rat model of middle cerebral
artery occlusion (MCAO) was established. Rats were
allocated to six groups: model, BMSC, VEGF
gene-transfected BMSC transplantation (BMSC/
VEGF), NMYH, combined NMYH and BMSC/VEGF
(combined treatment group) and sham operation
groups. The behavioral rating score (BRS) of rats
and the expression of CD34 and VEGF in brain tis-
sue were measured by immunohistochemistry on
days 7, 14 and 21 after reperfusion. Angiogenesis
was observed and evaluated with laser scanning
confocal microscopy.
RESULTS: The BRS of rats in NMYH, BMSC transplan-
tation and combined treatment groups was signifi-
cantly lower than that of the model group (P<
0.001), with no significant difference between
NMYH and transplantation groups (P=0.619). The
expression of CD34 and VEGF in NMYH, transplanta-
tion and combined treatment groups increased (P<
0.001), with a significant difference between NMYH
and transplantation groups (P<0.001). The blood
vessel area in NMYH, transplantation and com-
bined treatment groups was significantly increased
(P<0.05), without a significant difference between
NMYH and transplantation groups (P=0.873).
CONCLUSIONS: VEGF gene-transfected BMSCs im-
prove angiogenesis in the cerebral ischemic area.
NMYH Capsules promote angiogenesis in MCAO
rats treated with BMSC transplantation, which
show an improved BRS. The mechanism of angio-
genesis may be related to up-regulation of VEGF ex-
pression.
© 2012 JTCM. All rights reserved.
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INTRODUCTION
It is believed that an ideal treatment has not been devel-
oped for ischemic stroke[1], hence researchers attempt
to seek a solution by combining the latest biomedical
technologies with complementary/alternative methods.
One potential solution is bone marrow mesenchymal
stem cells (BMSCs) that can differentiate into neurons
and glial cells to replace necrotic neural cells due to
ischemia and hypoxia to promote the recovery of neu-
rological function [2]. BMSCs can also differentiate into
vascular endothelial cells that produce various nutri-
tional factors in autocrine and paracrine manners to
promote angiogenesis in the ischemic area [3]. Vascular
endothelial growth factor (VEGF) is currently the
strongest growth factor for vascular growth, hence it
is expected that transplantation of VEGF gene-trans-
fected BMSCs may have a robust effect on angiogen-
esis [4]. However, survival and differentiation rates of
newly transplanted cells are low because of local in-
tensive inflammation, an oxidative stress reaction
and proapoptotic and chemical factors caused by
ischemia, which lead to the restriction of therapeutic
effects [5]. Fortunately, current studies show that
there are various approaches by Chinese herbal medi-
cine which promote the proliferation and differentia-
tion of BMSCs [6,7] and help to form a microenviron-
ment suitable for the survival of transplanted cells. The
Naomai Yihao (NMYH) Capsule is a product of Chi-
nese herbs based on the Chinese medical theory to reg-
ulate the sea of blood in the brain. The capsule has
been proven effective for the treatment of ischemic
stroke in our previous clinical studies, and it improves
the patients' daily function impaired by cerebral isch-
emia and enhances the quality of life for stroke pa-
tients [8]. Animal experiments also show that NMYH
improves angiogenesis in focal cerebral ischemic rats
treated with BMSC transplantation to enhance the be-
havioral rating score (BRS), in which stronger effects
are expected with a longer treatment period [9].
In this study, we explored the combinatorial effect of
NMYH Capsules and VEGF gene-transfected BMSCs
on angiogenesis after cerebral ischemia, which may in-
troduce a new approach for stem cell therapy assisted
by Chinese herbal medicine to treat brain infarction.
MATERIALS ANDMETHODS
Experimental animals
Ninety-five specific pathogen free (SPF) Sprague-Daw-
ley rats were used in this study. Rats were 3–4 months
of age, weighed 250–330 g, and provided by the Ex-
perimental Animal Center of Southern Medical Univer-
sity, certificate number: 0051720.
Reagents and instruments
Naomai Yihao (NMYH) Capsules were composed of
Zhi Tianma (Rhizoma Gastroiae), Shuizhi (Hirudo),
Huangqi (Radix Astragali), Zhi Nanxing (Arisaema
cum Bile), Banxia (Rhizoma Pinelliae), Chuanqiong
(Rihzama Chuanxiong) and Yimucao (Herba Leonuri),
and prepared and provided by the Pharmacy Depart-
ment of the 2nd Affiliated Hospital of Guangzhou Uni-
versity of Chinese Medicine (Guangzhou, China). The
production lot was 090702. Each capsule contained
the equivalent of 1 g crude drug. The providers of re-
agents, materials and instruments are as follows: pEG-
FP-VEGF165 plasmid, the Stem Cell Research Center
of Sun Yat-sen University (Guangzhou, China); Lipo-
fectamine 2000, Invitrogen Co Ltd.(Grand Island, NY,
USA); plasmid extraction kits, Tiangen Biotech (Bei-
jing) Co Ltd. (Beijing, China); rabbit anti-rat VEGF
antibody (Lot No. BS-0279R) and rabbit anti-rat
CD34 antibody (Lot No. BS-0646R), Beijing Biosyn-
thesis Biotechnology Co Ltd. (Beijing, China); SABC
(Lot No. SP-9001) and DAB (Lot No. ZLI-9032) kits,
Zhongshan Goldenbridge Biotechnology Co Ltd. (Bei-
jing, China); fluorescein isothiocyanate-labeled dextran
(FITC-Dextran; molecular weight: 2 × 106), Sigma-Al-
drich Co., (St. Louis, MO, USA); laser scanning confo-
cal microscope (LSCM), LEICA Microsystems Ltd.,
(Wetzlar, Germany); and Image-Pro Plus 6.0 image
analysis software (Model No. 41M60032-00032), Me-
dia Cybernetics Inc., (Bethesda, MD, USA).
Isolation, culture and VEGF gene transfection of
BMSCs
Bilateral femoral bone marrow of SD rats aged 6–8
months was harvested and resuspended as single cells,
then cultured in 0.1% fetal bovine serum (FBS) in low
glucose Dulbecco's modified Eagle medium
(L-DMEM) in an incubator at 37° C with 5% CO2.
Differential attachment culture was used for cell purifi-
cation, and cells were subcultured at 90% confluence.
Third passage BMSCs were collected for transfection
after optimizing the conditions as follows: 80%–90%
confluence, 6 μg/mL DNA concentration and a 3 μg:
4 μL ratio for DNA: Lipofectamine 2000. The 0.1%
FBS L-DMEM was exchanged after 6 h, and incuba-
tion continued. Cells were collected after 48 h of trans-
fection.
Establishment of the MCAO rat model
The MCAO rat model was established by the Zea Lon-
ga method with some modification. The middle cere-
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bral artery of the rat was occluded, and after 2 h the fil-
ament was withdrawn to a length of 3–4 mm for re-
perfusion. The characteristics of successful model estab-
lishment were contralateral hemiplegia and contralater-
al circling while walking. For the sham operation
group, the operating procedure was the same as de-
scribed above without filament insertion into the carot-
id artery.
Group allocation and treatments
Rats were allocated to operation groups, and the sham
operation group in which the middle cerebral artery
was not occluded. Operation groups included model,
BMSC model, VEGF gene-transfected BMSC trans-
plantation (BMSC/VEGF), NMYH, and combined
NMYH and BMSC/VEGF (NMYH + BMSC/VEGF)
groups. Each operation group was randomly divided in-
to three subgroups based on the length of time for sam-
pling (day 7, 14 and 21 groups). At each time point,
five, five and eight specimens were respectively collect-
ed from each operation group, and another five speci-
mens from the sham operation group that was not sub-
divided for the various time points.
After 24 h of reperfusion, rats received an injection of
10 μL cell suspension into the right striatum (AP=0
mm, MR=2.0 mm, DV=4.5 mm) using a stereotactic
apparatus. The injection for BMSC/VEGF and
NMYH + BMSC/VEGF groups contained 5 × 105
VEGF gene-transfected BMSCs. The injection for the
BMSC model group contained 5×105 BMSCs. The in-
jection for NMYH and sham operation groups con-
tained L-DMEM without serum. After transplanta-
tion, rats in NMYH and NMYH + BMSC/VEGF
groups were administered the NMYH herbal com-
pound by gavage at 1.5 g/kg. Sham operation, BMSC
and BMSC/VEGF groups were simultaneously admin-
istered normal saline at an equivalent volume. The
drug delivery frequency was once per day. The drug
dosage and liquid volume were adjusted weekly accord-
ing to the body mass of the rats until specimens were
collected.
Behavioral rating scale (BRS) for the nerve function
of rats
The nerve function of rats after reperfusion was as-
sessed by the mNSS scale[10] that includes muscle
strength and tone, consciousness, masonic movement
and reflex on days 7, 14 and 21 after treatment. The
highest BRS score is 18. Higher scores indicate a more
serious nerve injury.
Detection of the expression of VEGF and CD34 by
immunohistochemistry
Biopsy specimens were dewaxed and hydrated, then
the antigens were recovered by microwave heating in ci-
trate buffer (pH=6.0). Endogenous peroxidase activity
was blocked by 3% hydrogen peroxide. Primary anti-
bodies (1:50; rabbit anti-rat VEGF and CD34) were
added to the specimens after blocking with goat serum
for 15 min. Then, specimens were stored overnight at
4°C, washed twice in cold PBS and incubated with a
biotinylated goat anti-rabbit IgG at room temperature
for 60 min followed by a horseradish peroxidase-la-
beled avidin working solution. Specimens were color-
ized by a DAB chromogen, stained with hematoxylin,
dehydrated in an alcohol gradient, transparentized
with xylene and mounted with neutral gum. The stria-
tum area of each processed specimen was observed
with LSCM (400 × magnification) for positive cell
counting in five random fields of vision.
Observation of angiogenesis with LSCM
After 2 days of treatment, rats were anaesthetized and
injected with FITC-dextran (50 mg/mL) in the tail
vein (1 mL for each rat). FITC-dextran is maintained
in a free state in plasma during vascular circulation.
One minute after injection, rats were sacrificed by de-
capitation. Brain hemispheres were fixed in paraformal-
dehyde for 48 h at 4°C and then stored in a 20% su-
crose solution. Serial coronal sections of specimens
were prepared with a frozen sectioning machine after
OTC embedding, in which the section region was be-
tween 5.2 and– 5.8 mm from the anterior fontanel.
Five 100 μm sections of each specimen were cut for ev-
ery 2 mm of tissue. LSCM (200× magnification) was
applied to scan both the ischemic and contralateral
sides (five regions each were selected for each side) un-
der the following settings: 488 nm excitation wave-
length, 522 nm emission wavelength, 512×512 pixels
X-Y plane, 4× average frame scanning, 1 μm Z-axis as
the step sequence with scanning for 30 layers. The ves-
sel diameter and area were measured with the image
analysis software Image-Pro Plus 6.0[11].
Statistical analysis
Statistical analysis was performed by SPSS version
11.0. After testing for data normality and variance ho-
mogeneity, multiple factor analysis of variance was
used to analyze the relationship between transplanta-
tion, NMYH capsules, observed time points and their
interactive effects. Measurement data were presented as
the means ± standard deviation (SD). The significance
level was α=0.05.
RESULTS
BRS scores of nerve function in rats
The BRS score of the sham operation group was 0 be-
cause there were no neurological deficits found. All sub-
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jects in the five operation groups which underwent the
ischemia and reperfusion procedure showed severe
symptoms of neurological deficits. BRS score changes
are listed in Table 1 for BMSC and BMSC/VEGF
transplantations, NMYH treatment and NMYH+BM-
SC/VEGF transplantation. The BRS scores of NMYH,
BMSC transplantation and NMYH + BMSC/VEGF
groups were lower than that of the model group (P<
0.001). A significant difference between NMYH and
transplantation was not observed (P=0.619).
Table 1 BRS scores and positive VEGF and CD34 expression among operation groups ( xˉ ± S , n=5)
Group
Model
BMSCs
BMSCs/VEGF
NMYH
NMYH+BMSCs/VEGF
Time (Day)
7
14
21
7
14
21
7
14
21
7
14
21
7
14
21
BRS
9.13±1.25
7.75±0.71
5.36±1.03
8.75±0.89
6.63±0.74
4.45±0.82
8.63±0.92
6.50±1.07
4.27±1.01
7.75±0.89
6.38±1.30
4.36±0.92
7.50±0.93
5.38±0.92
3.36±1.02
VEGF
32.40±3.91
20.20±2.59
15.80±1.92
48.80±3.96
29.40±3.36
23.60±3.65
55.60±6.02
32.20±3.96
25.20±2.39
50.60±4.16
28.20±3.35
24.20±2.77
58.20±6.22
33.20±3.27
29.20±3.35
CD34
15.20±2.77
19.20±3.11
14.20±2.17
23.40±2.07
27.40±3.44
23.80±2.49
27.20±2.59
29.20±3.83
25.40±3.05
24.80±2.39
27.80±3.96
25.20±3.70
28.40±3.29
34.20±4.60
30.40±4.04
CD34 expression
There was no CD34 expression in the sham operation
group. CD34 was expressed in all operation groups on
day 7 after the operation, which peaked on day 14 and
began to decrease on day 21. The pattern of CD34 ex-
pression in all operation groups was the same as that of
the model group (See Table 1). Transplantation,
NMYH capsules and observation time were influential
factors for CD34 expression (P<0.001). In addition,
the NMYH+BMSC/VEGF group showed the highest
CD34 expression among operation groups with inter-
acting effects (P<0.001). High CD34 expression is a
marker of angiogenesis, thus these results implied that
NMYH promotes vascular regeneration in the isch-
emic area after BMSC/VEGF transplantation. See Fig-
ure 1.
VEGF expression
There was no VEGF expression in the sham operation
group. VEGF expression peaked in all operation
groups on day 7 after the operation and decreased
from day 14 to 21. The pattern of VEGF expression in
operation groups was the same as that of the model
group (See Table 1). Transplantation, NMYH capsules
and observation time were influential factors for VEGF
expression (P<0.001). In addition, the NMYH+BM-
SC/VEGF group showed significantly higher VEGF ex-
pression among operation groups (P<0.001), which im-
plied that NMYH promoted angiogenesis in the isch-
emic area after transplantation of VEGF gene-transfect-
ed BMSCs. There were interacting effects between
transplantation and observation time (P<0.05), which
indicates that improved therapeutic effects can be ex-
pected as time progresses. See Figure 2.
Angiogenesis
Microvessel diameters in cerebral tissue increased after
ischemia, compared with those of the non-ischemic
side. Neither BMSC transplantation nor administra-
tion of NMYH capsules showed a significant effect on
changes in microvessel diameter, and showed no inter-
acting effects (P=0.198). However, both BMSC trans-
plantation and NMYH capsules significantly affected
vessel area (P<0.05). The combination of BMSC/
VEGF transplantation and NMYH resulted in the larg-
est vessel area, compared with those of other groups,
but both showed no interacting effects (P=0.873). (See
Table 2 and Figure. 3).
Table 2Outcomeof angiogenesis amonggroups ( xˉ ± S , n=3)
Group
Contralateral
Model
BMSCs
BMSCs/VEGF
NMYH
NMYH+BMSCs/VEGF
Vessel diam-
eter (μm)
1.29±0.09
1.31±0.10
1.46±0.11
1.46±0.10
1.47±0.11
1.49±0.12
Vessel area (μm2)
830.15±117.74
698.75±117.28
893.91±110.93
915.34±188.31
917.58±169.34
1111.01±192.13
DISCUSSION
Therapeutic angiogenesis is a current research focus of
therapies for ischemic disease. BMSCs can directly dif-
ferentiate into vascular endothelial cells, and secrete au-
tocrine and paracrine growth factors to promote angio-
genesis in the ischemic area[12]. VEGF is the strongest
angiogenesis factor that efficiently and directly binds
two receptors on vascular endothelial cells, namely Flt
and Flk/KDR that accelerate endothelial cell migration
and angiogenesis by stimulating the proliferation of en-
dothelial cells and producing plasminogen activator
and collagenase[13]. In addition, VEGF also directly en-
hances neurogenesis and protects neurons[14] by stimu-
lating axonal growth and reducing neural cell death in-
duced by hypoxia or excitatory amino acids. VEGF
gene expression is regulated by hypoxia-inducible fac-
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tors, in which angiogenesis occurs upon stimulation by
ischemia or hypoxia with increased VEGF expression
that gradually reduces within 2– 4 days. As a result,
this limited angiogenesis cannot restore endothelial cell
integrity and build effective collateral circulation[15].
Therefore, sufficient and timely supply of VEGF is
beneficial during the critical period of angiogenesis [11].
In our study, BMSCs transfected with the eukaryotic
expression vector pEGFP-VEGF165 were transplanted
into cerebral ischemic rats, and it was found that the
gene expression of VEGF and CD34 in the transfected
groups was higher than that in the non-transfected
groups. This outcome implies that angiogenesis in the
ischemic area is related to VEGF expression.
Chinese medicine has shown progress as a treatment to
enhance the effectiveness of BMSC transplantation to
treat ischemic diseases. Recent studies indicate that
Chinese medical herbs promote blood circulation and
remove blood stasis to facilitate angiogenesis by increas-
ing the level of growth factors in the brain [16], which in-
creases blood supply in microcirculation. Chinese med-
ical herbs that eliminate heat and detoxify can reduce
the expression of inflammatory factors and permeabili-
ty of the blood-brain barrier [6], which are favorable to
the survival of transplanted cells in the microenviron-
ment. Bi et al [7] found that salvia miltiorrhiza mono-
mer, namely Salvianolic acid B (Sal B), increases cell
survival rates in BMSC transplantation which were 2
and 3 times higher than those of the non-transplanted
group on days 7 and 28, respectively. It was hypothe-
sized that the mechanism was Sal B protecting BMSCs
from damage by tumor necrosis factor.
The NMYH capsule is a medicinal Chinese herbal
compound based on the therapeutic principle of regu-
lating blood flow [17], in which the clinical effectiveness
has been assessed and proven by a prospective
multi-center randomized controlled trial[8]. NMYH
capsules include Huangqi (Radix Astragali), Chuanq-
iong (Rihzama Chuanxiong), Zhi Nanxing (Arisaema
cum Bile) and Shuizhi (Hirudo), and their active com-
ponents inhibit inflammatory responses [18], reduce
apoptosis [19], eliminate oxygen free radicals and im-
prove microcirculation[20]. Therefore, the combination
of NMYH capsule administration and BMSC trans-
plantation may promote angiogenesis and increase the
survival of transplanted cells in ischemic cerebral tissue
and reduce neuronal apoptosis.
Our study showed that the expression of VEGF and
CD34 significantly increased in the NMYH group,
compared with that of the model group, and the ex-
pression of VEGF and CD34 in the combined
NMYH + BMSC/VEGF group increased significantly,
compared with that of BMSC transplantation alone.
These findings imply that NMYH may play a role in
the treatment of cerebral ischemia. The mechanism
may be enhanced blood supply to ischemic cerebral tis-
sues by improving angiogenesis after transplantation of
VEGF gene-transfected BMSCs, and an improvement
Figure 1 CD34 expression in the brain of rats among groups on day 21 (SABC staining, x400). A: Model group, B: BMSC group, C:
BMSC/VEGF group, D: NMYH group, E: BMSC/VEGF+NMYH group.
Figure 2 VEGF expression in the brain of rats among groups on day 21 (SABC staining, ×400). A: model group, B: BMSC group, C:
BMSC/VEGF group, D: NMYH Capsule group, E: BMSC/VEGF+NMYH group.
Figure 3 Observation of angiogenesis in the brain of rats among groups using laser scanning confocal microscopy (×200). A: Mod-
el group, B: BMSC group, C: BMSC/ VEGF group, D: NMYH Capsule group, E: BMSC/VEGF+NMYH group.
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of impaired nerve function. The interacting effects be-
tween VEGF expression and treatment duration indi-
cated that enhanced therapeutic effects may be ob-
served after a longer time-period. The absence of an in-
teracting effect between NMYH and BMSC/VEGF
transplantation to improve BRS and the vessel area of
rats is possibly related to the limitation of the observa-
tion period and NMYH dosage. Therefore, further
study should explore the effects on angiogenesis after
BMSC/VEGF transplantation at various dosages of
NMYH with a longer observation period.
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